{‘She possesses zero qualifications’: the US scientific field braces for Dr. Høeg's tenure at the Food and Drug Administration.

Given that America proceeds with historic revisions to its immunization recommendations, a particular individual appears in a surprising turn: Høeg, a Danish American sports physician and epidemiologist who first made her name by casting doubt on COVID-19 shots throughout the global health crisis and has concentrated on alleged fatalities after Covid immunization in her short time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Program

Public health authorities planned to announce major changes to the childhood immunization program earlier this month, synchronizing the US with the Danish national calendar, it is understood – a substantial departure that would place the US out of step with many the world with insufficient data for improved outcomes. This reveal has been delayed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A Shift at the FDA

Høeg's temporary position could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for halting some childhood immunization guidelines in the US so as to align more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

So far statements, she has continued to focus on immunizations – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Expertise

Høeg has little discernible experience in pharmaceutical research, regulation or leadership, which has been standard for past heads of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in running a major agency. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “understand regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that former directors who headed the center have had.”

CDER has an enormous portfolio at the agency, the former commissioner emphasized.

“Many people just pays attention on the innovative therapies, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and all of those have to be supervised,” Dr. Woodcock noted. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant administrative element to the role, which supervises in excess of 5,000 personnel. “It is a enormous management job, if you execute it properly,” Woodcock said.

Official Statement and Controversial Initiatives

When asked about concerns about Høeg’s credentials and whether this appointment signifies increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “inquiries rely on flawed premises”.

“Her experience is consistent with the functions of her position,” the spokesperson explained, noting the months Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed rapid medication authorization process that apparently troubled her predecessors. “How are these drugs being picked for this fast-track system? Who is making the calls?” Howard asked. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he said, “the FDA appears to be shifting towards laxer oversight of most medications, with the exception of immunizations.”

Public History on Immunizations

With immunizations, Høeg has a more established, if troubling, history, critics observe. She published a study using non-validated public submissions to assess the rate of heart inflammation following COVID-19 immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are riskier than they are.

Among her “policy goals” for the new administration included revising guidelines for novel immunizations and discontinuing “optional” immunizations, she stated after the election on a podcast. At the agency, Høeg has reportedly suggested barring teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and tailors the evidence to accommodate the data in a highly deceptive, untruthful fashion,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|